APO Research
Talk to an analyst

APO RESEARCH · REPORT

TKI for Chronic Myeloid Leukemia

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global TKI for Chronic Myeloid Leukemia Market Outlook and Growth Opportunities 2026

27 December 2025208 pages

Choose your research edition.

Industry ResearchTKI for Chronic Myeloid Leukemia Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal TKI for Chronic Myeloid Leukemia Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal TKI for Chronic Myeloid Leukemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TKI for Chronic Myeloid Leukemia Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal TKI for Chronic Myeloid Leukemia Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global TKI for Chronic Myeloid Leukemia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the TKI for Chronic Myeloid Leukemia market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the TKI for Chronic Myeloid Leukemia market include Apotex, Bristol Myers Squibb, Dr. Reddy's Laboratories, Eugia Pharma, Hetero, Lupin, Mylan, Novartis and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global TKI for Chronic Myeloid Leukemia market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of TKI for Chronic Myeloid Leukemia and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents TKI for Chronic Myeloid Leukemia sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the TKI for Chronic Myeloid Leukemia market size, projected growth trends, production technologies, key applications, and end-use industries.

TKI for Chronic Myeloid Leukemia Segment by Company

Apotex

Bristol Myers Squibb

Dr. Reddy's Laboratories

Eugia Pharma

Hetero

Lupin

Mylan

Novartis

Pfizer

Sawai Pharmaceutical

Sun Pharmaceuticals

Takeda Pharmaceuticals

Teva

Hansoh Pharmaceutical

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Suzhou Thery Pharmaceutical

Chia Tai Tianqing Pharmaceutical

TKI for Chronic Myeloid Leukemia Segment by Type

Imatinib

Ponatinib

Nilotinib

Flumatinib

Dasatinib

Bosutinib

Asciminib

Other

TKI for Chronic Myeloid Leukemia Segment by Application

Hospitals and clinics

Pharmacies

Others

TKI for Chronic Myeloid Leukemia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global TKI for Chronic Myeloid Leukemia status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions TKI for Chronic Myeloid Leukemia market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify TKI for Chronic Myeloid Leukemia significant trends, drivers, influence factors in global and regions.

6. To analyze TKI for Chronic Myeloid Leukemia competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TKI for Chronic Myeloid Leukemia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TKI for Chronic Myeloid Leukemia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TKI for Chronic Myeloid Leukemia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the TKI for Chronic Myeloid Leukemia market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global TKI for Chronic Myeloid Leukemia industry.

Chapter 3: Detailed analysis of TKI for Chronic Myeloid Leukemia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of TKI for Chronic Myeloid Leukemia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of TKI for Chronic Myeloid Leukemia in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. TKI for Chronic Myeloid Leukemia Industry Trends Table 2. TKI for Chronic Myeloid Leukemia Industry Drivers Table 3. TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges Table 4. TKI for Chronic Myeloid Leukemia Industry Restraints Table 5. Global TKI for Chronic Myeloid Leukemia Revenue by Company (US$ Million) & (2021-2026) Table 6. Global TKI for Chronic Myeloid Leukemia Revenue Share by Company (2021-2026) Table 7. Global TKI for Chronic Myeloid Leukemia Sales Volume by Company (K Units) & (2021-2026) Table 8. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Company (2021-2026) Table 9. Global TKI for Chronic Myeloid Leukemia Average Price (US$/Unit) of Company (2021-2026) Table 10. Global TKI for Chronic Myeloid Leukemia Company Ranking, (2024-2026) & (USD Million) Table 11. Global TKI for Chronic Myeloid Leukemia Key Company Manufacturing Base & Headquarters Table 12. Global TKI for Chronic Myeloid Leukemia Company, Product Type & Application Table 13. Global TKI for Chronic Myeloid Leukemia Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global TKI for Chronic Myeloid Leukemia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Imatinib Table 18. Significant Companies of Ponatinib Table 19. Significant Companies of Nilotinib Table 20. Significant Companies of Flumatinib Table 21. Significant Companies of Dasatinib Table 22. Significant Companies of Bosutinib Table 23. Significant Companies of Asciminib Table 24. Significant Companies of Other Table 25. Global TKI for Chronic Myeloid Leukemia Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global TKI for Chronic Myeloid Leukemia Sales Volume by Type (2021-2026) & (K Units) Table 27. Global TKI for Chronic Myeloid Leukemia Sales Volume by Type (2027-2032) & (K Units) Table 28. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Type (2021-2026) Table 29. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Type (2027-2032) Table 30. Global TKI for Chronic Myeloid Leukemia Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global TKI for Chronic Myeloid Leukemia Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global TKI for Chronic Myeloid Leukemia Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Type (2021-2026) Table 34. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Hospitals and clinics Table 36. Significant Companies of Pharmacies Table 37. Significant Companies of Others Table 38. Global TKI for Chronic Myeloid Leukemia Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global TKI for Chronic Myeloid Leukemia Sales Volume by Application (2021-2026) & (K Units) Table 40. Global TKI for Chronic Myeloid Leukemia Sales Volume by Application (2027-2032) & (K Units) Table 41. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Application (2021-2026) Table 42. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Application (2027-2032) Table 43. Global TKI for Chronic Myeloid Leukemia Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global TKI for Chronic Myeloid Leukemia Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global TKI for Chronic Myeloid Leukemia Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Application (2021-2026) Table 47. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Application (2027-2032) Table 48. Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (K Units) Table 50. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2026) Table 51. Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032) & (K Units) Table 52. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2027-2032) Table 53. Global TKI for Chronic Myeloid Leukemia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global TKI for Chronic Myeloid Leukemia Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Region (2021-2026) Table 56. Global TKI for Chronic Myeloid Leukemia Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Region (2027-2032) Table 58. Global TKI for Chronic Myeloid Leukemia Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global TKI for Chronic Myeloid Leukemia Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global TKI for Chronic Myeloid Leukemia Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 63. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 64. Global TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032) & (K Units) Table 65. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2027-2032) Table 66. Global TKI for Chronic Myeloid Leukemia Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global TKI for Chronic Myeloid Leukemia Sales Value Market Share by Country (2021-2026) Table 68. Global TKI for Chronic Myeloid Leukemia Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global TKI for Chronic Myeloid Leukemia Sales Value Market Share by Country (2027-2032) Table 70. Apotex Company Information Table 71. Apotex Business Overview Table 72. Apotex TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Apotex TKI for Chronic Myeloid Leukemia Product Portfolio Table 74. Apotex Recent Development Table 75. Bristol Myers Squibb Company Information Table 76. Bristol Myers Squibb Business Overview Table 77. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio Table 79. Bristol Myers Squibb Recent Development Table 80. Dr. Reddy's Laboratories Company Information Table 81. Dr. Reddy's Laboratories Business Overview Table 82. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio Table 84. Dr. Reddy's Laboratories Recent Development Table 85. Eugia Pharma Company Information Table 86. Eugia Pharma Business Overview Table 87. Eugia Pharma TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio Table 89. Eugia Pharma Recent Development Table 90. Hetero Company Information Table 91. Hetero Business Overview Table 92. Hetero TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hetero TKI for Chronic Myeloid Leukemia Product Portfolio Table 94. Hetero Recent Development Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Lupin TKI for Chronic Myeloid Leukemia Product Portfolio Table 99. Lupin Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Mylan TKI for Chronic Myeloid Leukemia Product Portfolio Table 104. Mylan Recent Development Table 105. Novartis Company Information Table 106. Novartis Business Overview Table 107. Novartis TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Novartis TKI for Chronic Myeloid Leukemia Product Portfolio Table 109. Novartis Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio Table 114. Pfizer Recent Development Table 115. Sawai Pharmaceutical Company Information Table 116. Sawai Pharmaceutical Business Overview Table 117. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 119. Sawai Pharmaceutical Recent Development Table 120. Sun Pharmaceuticals Company Information Table 121. Sun Pharmaceuticals Business Overview Table 122. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 124. Sun Pharmaceuticals Recent Development Table 125. Takeda Pharmaceuticals Company Information Table 126. Takeda Pharmaceuticals Business Overview Table 127. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 129. Takeda Pharmaceuticals Recent Development Table 130. Teva Company Information Table 131. Teva Business Overview Table 132. Teva TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Teva TKI for Chronic Myeloid Leukemia Product Portfolio Table 134. Teva Recent Development Table 135. Hansoh Pharmaceutical Company Information Table 136. Hansoh Pharmaceutical Business Overview Table 137. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 139. Hansoh Pharmaceutical Recent Development Table 140. Lunan Pharmaceutical Company Information Table 141. Lunan Pharmaceutical Business Overview Table 142. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 144. Lunan Pharmaceutical Recent Development Table 145. Qilu Pharmaceutical Company Information Table 146. Qilu Pharmaceutical Business Overview Table 147. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 149. Qilu Pharmaceutical Recent Development Table 150. CSPC Ouyi Pharmaceutical Company Information Table 151. CSPC Ouyi Pharmaceutical Business Overview Table 152. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 154. CSPC Ouyi Pharmaceutical Recent Development Table 155. Suzhou Thery Pharmaceutical Company Information Table 156. Suzhou Thery Pharmaceutical Business Overview Table 157. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 159. Suzhou Thery Pharmaceutical Recent Development Table 160. Chia Tai Tianqing Pharmaceutical Company Information Table 161. Chia Tai Tianqing Pharmaceutical Business Overview Table 162. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 164. Chia Tai Tianqing Pharmaceutical Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. TKI for Chronic Myeloid Leukemia Distributors List Table 168. TKI for Chronic Myeloid Leukemia Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. TKI for Chronic Myeloid Leukemia Product Image Figure 2. Global TKI for Chronic Myeloid Leukemia Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 4. Global TKI for Chronic Myeloid Leukemia Sales (2021-2032) & (K Units) Figure 5. Global TKI for Chronic Myeloid Leukemia Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global TKI for Chronic Myeloid Leukemia Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Imatinib Image Figure 10. Ponatinib Image Figure 11. Nilotinib Image Figure 12. Flumatinib Image Figure 13. Dasatinib Image Figure 14. Bosutinib Image Figure 15. Asciminib Image Figure 16. Other Image Figure 17. Global TKI for Chronic Myeloid Leukemia Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global TKI for Chronic Myeloid Leukemia Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Type (2021-2032) Figure 20. Global TKI for Chronic Myeloid Leukemia Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global TKI for Chronic Myeloid Leukemia Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Type (2021-2032) Figure 23. Hospitals and clinics Image Figure 24. Pharmacies Image Figure 25. Others Image Figure 26. Global TKI for Chronic Myeloid Leukemia Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global TKI for Chronic Myeloid Leukemia Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Application (2021-2032) Figure 29. Global TKI for Chronic Myeloid Leukemia Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global TKI for Chronic Myeloid Leukemia Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Application (2021-2032) Figure 32. Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global TKI for Chronic Myeloid Leukemia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global TKI for Chronic Myeloid Leukemia Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 37. North America TKI for Chronic Myeloid Leukemia Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 39. Europe TKI for Chronic Myeloid Leukemia Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 43. South America TKI for Chronic Myeloid Leukemia Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. TKI for Chronic Myeloid Leukemia Value Chain Figure 131. Manufacturing Cost Structure Figure 132. TKI for Chronic Myeloid Leukemia Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Imatinib
  • Ponatinib
  • Nilotinib
  • Flumatinib
  • Dasatinib
  • Bosutinib
  • Asciminib
  • Other
Applications
  • Hospitals and clinics
  • Pharmacies
  • Others
Companies covered
  • Apotex
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Hetero
  • Lupin
  • Mylan
  • Novartis
  • Pfizer
  • Sawai Pharmaceutical
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva
  • Hansoh Pharmaceutical
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Suzhou Thery Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  4. 1.2.2 Global TKI for Chronic Myeloid Leukemia Sales Volume (2021-2032)
  5. 1.2.3 Global TKI for Chronic Myeloid Leukemia Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 TKI for Chronic Myeloid Leukemia Market Dynamics
  1. 2.1 TKI for Chronic Myeloid Leukemia Industry Trends
  2. 2.2 TKI for Chronic Myeloid Leukemia Industry Drivers
  3. 2.3 TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges
  4. 2.4 TKI for Chronic Myeloid Leukemia Industry Restraints
3 TKI for Chronic Myeloid Leukemia Market by Company
  1. 3.1 Global TKI for Chronic Myeloid Leukemia Company Revenue Ranking in 2025
  2. 3.2 Global TKI for Chronic Myeloid Leukemia Revenue by Company (2021-2026)
  3. 3.3 Global TKI for Chronic Myeloid Leukemia Sales Volume by Company (2021-2026)
  4. 3.4 Global TKI for Chronic Myeloid Leukemia Average Price by Company (2021-2026)
  5. 3.5 Global TKI for Chronic Myeloid Leukemia Company Ranking (2024-2026)
  6. 3.6 Global TKI for Chronic Myeloid Leukemia Company Manufacturing Base and Headquarters
  7. 3.7 Global TKI for Chronic Myeloid Leukemia Company Product Type and Application
  8. 3.8 Global TKI for Chronic Myeloid Leukemia Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global TKI for Chronic Myeloid Leukemia Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 TKI for Chronic Myeloid Leukemia Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 TKI for Chronic Myeloid Leukemia Market by Type
  1. 4.1 TKI for Chronic Myeloid Leukemia Type Introduction
  2. 4.1.1 Imatinib
  3. 4.1.2 Ponatinib
  4. 4.1.3 Nilotinib
  5. 4.1.4 Flumatinib
  6. 4.1.5 Dasatinib
  7. 4.1.6 Bosutinib
  8. 4.1.7 Asciminib
  9. 4.1.8 Other
  10. 4.2 Global TKI for Chronic Myeloid Leukemia Sales Volume by Type
  11. 4.2.1 Global TKI for Chronic Myeloid Leukemia Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global TKI for Chronic Myeloid Leukemia Sales Volume by Type (2021-2032)
  13. 4.2.3 Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Type (2021-2032)
  14. 4.3 Global TKI for Chronic Myeloid Leukemia Sales Value by Type
  15. 4.3.1 Global TKI for Chronic Myeloid Leukemia Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global TKI for Chronic Myeloid Leukemia Sales Value by Type (2021-2032)
  17. 4.3.3 Global TKI for Chronic Myeloid Leukemia Sales Value Share by Type (2021-2032)
5 TKI for Chronic Myeloid Leukemia Market by Application
  1. 5.1 TKI for Chronic Myeloid Leukemia Application Introduction
  2. 5.1.1 Hospitals and clinics
  3. 5.1.2 Pharmacies
  4. 5.1.3 Others
  5. 5.2 Global TKI for Chronic Myeloid Leukemia Sales Volume by Application
  6. 5.2.1 Global TKI for Chronic Myeloid Leukemia Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TKI for Chronic Myeloid Leukemia Sales Volume by Application (2021-2032)
  8. 5.2.3 Global TKI for Chronic Myeloid Leukemia Sales Volume Share by Application (2021-2032)
  9. 5.3 Global TKI for Chronic Myeloid Leukemia Sales Value by Application
  10. 5.3.1 Global TKI for Chronic Myeloid Leukemia Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global TKI for Chronic Myeloid Leukemia Sales Value by Application (2021-2032)
  12. 5.3.3 Global TKI for Chronic Myeloid Leukemia Sales Value Share by Application (2021-2032)
6 TKI for Chronic Myeloid Leukemia Regional Sales and Value Analysis
  1. 6.1 Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2032)
  3. 6.2.1 Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021-2026
  4. 6.2.2 Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032)
  5. 6.3 Global TKI for Chronic Myeloid Leukemia Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global TKI for Chronic Myeloid Leukemia Sales Value by Region (2021-2032)
  7. 6.4.1 Global TKI for Chronic Myeloid Leukemia Sales Value by Region: 2021-2026
  8. 6.4.2 Global TKI for Chronic Myeloid Leukemia Sales Value by Region (2027-2032)
  9. 6.5 Global TKI for Chronic Myeloid Leukemia Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  12. 6.6.2 North America TKI for Chronic Myeloid Leukemia Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  15. 6.7.2 Europe TKI for Chronic Myeloid Leukemia Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  21. 6.9.2 South America TKI for Chronic Myeloid Leukemia Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa TKI for Chronic Myeloid Leukemia Sales Value Share by Country, 2025 VS 2032
7 TKI for Chronic Myeloid Leukemia Country-level Sales and Value Analysis
  1. 7.1 Global TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global TKI for Chronic Myeloid Leukemia Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global TKI for Chronic Myeloid Leukemia Sales by Country (2021-2032)
  4. 7.3.1 Global TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  5. 7.3.2 Global TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032)
  6. 7.4 Global TKI for Chronic Myeloid Leukemia Sales Value by Country (2021-2032)
  7. 7.4.1 Global TKI for Chronic Myeloid Leukemia Sales Value by Country (2021-2026)
  8. 7.4.2 Global TKI for Chronic Myeloid Leukemia Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt TKI for Chronic Myeloid Leukemia Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt TKI for Chronic Myeloid Leukemia Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt TKI for Chronic Myeloid Leukemia Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Apotex
  2. 8.1.1 Apotex Company Information
  3. 8.1.2 Apotex Business Overview
  4. 8.1.3 Apotex TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Apotex TKI for Chronic Myeloid Leukemia Product Portfolio
  6. 8.1.5 Apotex Recent Developments
  7. 8.2 Bristol Myers Squibb
  8. 8.2.1 Bristol Myers Squibb Company Information
  9. 8.2.2 Bristol Myers Squibb Business Overview
  10. 8.2.3 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio
  12. 8.2.5 Bristol Myers Squibb Recent Developments
  13. 8.3 Dr. Reddy's Laboratories
  14. 8.3.1 Dr. Reddy's Laboratories Company Information
  15. 8.3.2 Dr. Reddy's Laboratories Business Overview
  16. 8.3.3 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio
  18. 8.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 8.4 Eugia Pharma
  20. 8.4.1 Eugia Pharma Company Information
  21. 8.4.2 Eugia Pharma Business Overview
  22. 8.4.3 Eugia Pharma TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio
  24. 8.4.5 Eugia Pharma Recent Developments
  25. 8.5 Hetero
  26. 8.5.1 Hetero Company Information
  27. 8.5.2 Hetero Business Overview
  28. 8.5.3 Hetero TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hetero TKI for Chronic Myeloid Leukemia Product Portfolio
  30. 8.5.5 Hetero Recent Developments
  31. 8.6 Lupin
  32. 8.6.1 Lupin Company Information
  33. 8.6.2 Lupin Business Overview
  34. 8.6.3 Lupin TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lupin TKI for Chronic Myeloid Leukemia Product Portfolio
  36. 8.6.5 Lupin Recent Developments
  37. 8.7 Mylan
  38. 8.7.1 Mylan Company Information
  39. 8.7.2 Mylan Business Overview
  40. 8.7.3 Mylan TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mylan TKI for Chronic Myeloid Leukemia Product Portfolio
  42. 8.7.5 Mylan Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis TKI for Chronic Myeloid Leukemia Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Sawai Pharmaceutical
  56. 8.10.1 Sawai Pharmaceutical Company Information
  57. 8.10.2 Sawai Pharmaceutical Business Overview
  58. 8.10.3 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  60. 8.10.5 Sawai Pharmaceutical Recent Developments
  61. 8.11 Sun Pharmaceuticals
  62. 8.11.1 Sun Pharmaceuticals Company Information
  63. 8.11.2 Sun Pharmaceuticals Business Overview
  64. 8.11.3 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  66. 8.11.5 Sun Pharmaceuticals Recent Developments
  67. 8.12 Takeda Pharmaceuticals
  68. 8.12.1 Takeda Pharmaceuticals Company Information
  69. 8.12.2 Takeda Pharmaceuticals Business Overview
  70. 8.12.3 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  72. 8.12.5 Takeda Pharmaceuticals Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Teva TKI for Chronic Myeloid Leukemia Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Hansoh Pharmaceutical
  80. 8.14.1 Hansoh Pharmaceutical Company Information
  81. 8.14.2 Hansoh Pharmaceutical Business Overview
  82. 8.14.3 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  84. 8.14.5 Hansoh Pharmaceutical Recent Developments
  85. 8.15 Lunan Pharmaceutical
  86. 8.15.1 Lunan Pharmaceutical Company Information
  87. 8.15.2 Lunan Pharmaceutical Business Overview
  88. 8.15.3 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  90. 8.15.5 Lunan Pharmaceutical Recent Developments
  91. 8.16 Qilu Pharmaceutical
  92. 8.16.1 Qilu Pharmaceutical Company Information
  93. 8.16.2 Qilu Pharmaceutical Business Overview
  94. 8.16.3 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  96. 8.16.5 Qilu Pharmaceutical Recent Developments
  97. 8.17 CSPC Ouyi Pharmaceutical
  98. 8.17.1 CSPC Ouyi Pharmaceutical Company Information
  99. 8.17.2 CSPC Ouyi Pharmaceutical Business Overview
  100. 8.17.3 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  102. 8.17.5 CSPC Ouyi Pharmaceutical Recent Developments
  103. 8.18 Suzhou Thery Pharmaceutical
  104. 8.18.1 Suzhou Thery Pharmaceutical Company Information
  105. 8.18.2 Suzhou Thery Pharmaceutical Business Overview
  106. 8.18.3 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  108. 8.18.5 Suzhou Thery Pharmaceutical Recent Developments
  109. 8.19 Chia Tai Tianqing Pharmaceutical
  110. 8.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 8.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 8.19.3 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  114. 8.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 TKI for Chronic Myeloid Leukemia Value Chain Analysis
  2. 9.1.1 TKI for Chronic Myeloid Leukemia Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 TKI for Chronic Myeloid Leukemia Sales Mode & Process
  6. 9.2 TKI for Chronic Myeloid Leukemia Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 TKI for Chronic Myeloid Leukemia Distributors
  9. 9.2.3 TKI for Chronic Myeloid Leukemia Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst